Pyrantel Pamoate: Difference between revisions

Latest revision as of 12:12, 20 March 2026

Administration

Type: Antiparasitic
Dosage Forms:
Routes of Administration: Oral
Common Trade Names:

Adult Dosing

11mg/kg once

Indications by Disease

Disease	Dose	Context
Enterobius	11mg/kg (max 1g) PO once then repeat in 2 weeks	Adult first choice for pregnant

Pediatric Dosing

> 2yo: 11mg/kg once

Indications by Disease

Special Populations

Pregnancy Rating: C
Lactation risk: Infant risk cannot be ruled out
Renal dosing:
Hepatic dosing:

Contraindications

Allergy to class/drug

Adverse Reactions

Serious

Common

Nausea/vomiting, diarrhea
Headache, dizziness, somnolence

Pharmacology

Half-life:
Metabolism:
Excretion: Fecal

Mechanism of Action

depolarizing neuromuscular blocking agent, causes spastic paralysis in the worms

Comments

Indicated to treat infection with enterobius, ascaris, and other similar worms

References

Authors:

@@ Line 1: / Line 1: @@
-==General==
+==Administration==
-*AKA: aloprostadil
+*Type: [[Antiparasitic]]
-*Type: smooth muscle relaxer, vasodilator
+*Dosage Forms:
-*Dosage Forms: intravenous, penile injection, penile suppository
+*Routes of Administration: Oral
-*Common Trade Names: [https://alprostadil.org Alprostadil], Prostin VR, Caverject, Muse, Edex
+*Common Trade Names:
-*Uses: maintenance of [[patent ductus arteriosus]] in neonates with duct-dependent congenital heart defects; treatment of erectile dysfunction in adults
 ==Adult Dosing==
+*11mg/kg once
-==Pediatric Dosing<ref> Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC Sr, Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing.Circulation. 2014 May 27;129(21):2183-242. doi: 10.1161/01.cir.0000437597.44550.5d. Epub 2014 Apr 24.</ref>==
-*Start infusion at 0.05 mcg/kg/min IV
-**Titrate to 0.1 mcg/kg/min as tolerated, monitoring for hypotension (and apnea)
 ===Indications by Disease===
@@ Line 26: / Line 21: @@
 ==Pediatric Dosing==
+*> 2yo: 11mg/kg once
 ===Indications by Disease===
@@ Line 41: / Line 37: @@
 ==Special Populations==
 *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
-*Lactation: infant risk cannot be ruled out
+*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out
-*Renal Dosing
+*Renal dosing:
-**Adult
+*Hepatic dosing:
-**Pediatric
-*Hepatic Dosing
-**Adult
-**Pediatric
 ==Contraindications==
@@ Line 53: / Line 45: @@
 ==Adverse Reactions==
-*Beware of three common side effects that may require further resuscitation<ref>Martin RJ et al. Pathophysiologic Mechanisms Underlying Apnea of Prematurity. NeoReviews Vol.3 No.4 April 2002.</ref><ref>Segar JL. Protocol for Use of Prostaglandin E. University of Iowa Stead Family Children's Hospital. Accessed Dec 2016. https://uichildrens.org/health-library/protocol-use-prostaglandin-e?id=234424</ref>:
+===Serious===
-**Apnea (12%), which requires respiratory monitoring with ETCO2 capnography, potential mechanical ventilation, and/or ALS/PALS transport if needing transfer to higher level of care
-**Peripheral flushing with or without hypotension (10%), which requires fluid resuscitation
+===Common===
-**[[Fever]] (14%)
+*Nausea/vomiting, diarrhea
-*Others:
+*Headache, dizziness, somnolence
-**[[Hypotension]]
-**[[Bradycardia]]
-**[[Seizures]]
 ==Pharmacology==
-*Half-life: 5-10m
+*Half-life:
-*Metabolism: Lung
+*Metabolism:
-*Excretion: Renal
+*Excretion: Fecal
-*Mechanism of Action: synthetic of endogenous prostaglandin
+==Mechanism of Action==
+*depolarizing neuromuscular blocking agent, causes spastic paralysis in the worms
 ==Comments==
-*Cyanotic neonates with ductal-dependent lesions typically respond within 10-15 minutes, but may not show response until several hours after the start of infusion.
+*Indicated to treat infection with [[enterobius]], [[ascaris]], and other similar worms
 ==See Also==
-*[[Tetralogy of fallot]]
+*[[Parasitic diseases]]
 ==References==
 <references/>
 [[Category:Pharmacology]]
-[[Category:Pediatrics]]
+[[Category:ID]]
-[[Category:Cardiology]]